Search
Search Constraints
You searched for: Author/Creator Keystone, E CLimit your search
- Keystone, E C [remove] 21
- 616.723005 21
- Rheumatism -- Periodicals 21
- TNF blocking -- RA -- psoriatic arthritis -- ankylosing spondylitis -- inflammation -- immunity -- IL-1ra -- guideline 2
- ACR, American College of Rheumatology -- AEs, adverse events -- CI, confidence interval -- CRP, C reactive protein -- DAS28, 28 joint count Disease Activity Score -- DMARDs, disease modifying antirheumatic drugs -- HAQ, Health Assessment Questionnaire -- LOE, lack of efficacy -- MTX, methotrexate -- PPD, purified protein derivative -- RA, rheumatoid arthritis -- SIR, standardised incidence ratio -- SJC, swollen joint count -- TJC, tender joint count -- TNF, tumour necrosis factor 1
- ACR, American College of Rheumatology -- AS, ankylosing spondylitis -- CHF, congestive heart failure -- DAS, Disease Activity Score -- DMARD, disease modifying antirheumatic drug -- HAQ-DI, Health Assessment Questionnaire disability index -- MTX, methotrexate -- PsA, psoriatic arthritis -- RA, rheumatoid arthritis -- SF-36, Medical Outcome Survey Short Form 36 -- TNF, tumour necrosis factor -- VAS, visual analogue scale 1
- ACR, American College of Rheumatology -- SCDAI, Simplified composite Disease Activity Index -- DAS28, 28-joint Disease Activity Score -- DMARD, disease-modifying antirheumatic drug -- HACA, human antichimeric antibody -- MTX, methotrexate -- SDAI, simplified Disease Activity Index -- TNF, tumour necrosis factor 1
- BVAS, Birmingham Vasculitis Activity Score -- GCA, giant cell arteritis -- TNF, tumour necrosis factor -- VAS, visual analogue scale 1
- CHF, congestive heart failure -- FDA, Federal Drug Administration -- NDRD, National Databank for Rheumatic Disease -- RA, rheumatoid arthritis -- SEER, Surveillance, Epidemiology and End Results (database) -- SIR, standardised incidence rate -- TNF, tumour necrosis factor 1
- TNF antagonists -- orphan diseases -- sarcoidosis -- Sjögren's syndrome -- vasculitis 1
- TNF blocking -- abatacept -- rituximab -- IL-1ra -- RA -- psoriatic arthritis -- ankylosing spondylitis -- inflammation -- immunity -- guideline 1